HC Wainwright Has Bearish Forecast for XFOR FY2028 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Equities research analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for X4 Pharmaceuticals in a report issued on Friday, February 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn $0.02 per share for the year, down from their previous forecast of $0.04. HC Wainwright has a “Buy” rating and a $1.50 price objective on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2029 earnings at $0.16 EPS.

Separately, Stifel Nicolaus reduced their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Stock Down 8.0 %

Shares of NASDAQ:XFOR opened at $0.47 on Monday. The stock has a 50-day simple moving average of $0.60 and a 200-day simple moving average of $0.60. The stock has a market capitalization of $79.94 million, a P/E ratio of -5.21 and a beta of 0.12. X4 Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $1.60. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

Insider Buying and Selling at X4 Pharmaceuticals

In other news, CFO Adam S. Mostafa sold 74,773 shares of X4 Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $33,647.85. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Paula Ragan sold 76,473 shares of the company’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the transaction, the chief executive officer now owns 1,087,386 shares of the company’s stock, valued at $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock valued at $91,198 over the last three months. 1.62% of the stock is owned by company insiders.

Institutional Investors Weigh In On X4 Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the business. State Street Corp raised its position in shares of X4 Pharmaceuticals by 6.8% in the 3rd quarter. State Street Corp now owns 2,952,895 shares of the company’s stock valued at $1,976,000 after purchasing an additional 189,105 shares in the last quarter. Verition Fund Management LLC bought a new stake in shares of X4 Pharmaceuticals in the third quarter worth $30,000. SG Americas Securities LLC acquired a new stake in X4 Pharmaceuticals in the third quarter valued at $37,000. XTX Topco Ltd boosted its stake in X4 Pharmaceuticals by 41.7% during the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock valued at $106,000 after acquiring an additional 46,397 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in X4 Pharmaceuticals by 103.4% during the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after acquiring an additional 126,296 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.